flow trial semaglutide kidney outcomes nejm 2024 hazard ratio 0.76 Patients with type 2 #diabetes and chronic disease are at high risk for kidney failure, cardiovascular events, and death. ⁣ ⁣ Whether treatment with would mitigate these risks is unknown. ⁣ ⁣ Semaglutide in kidney outcomes Obesity

If you have tried Empower and your results have plateaued despite dose optimization and lifestyle modifications, discussing a switch to brand-name Mounjaro or another compounder with your prescriber is reasonable

Meeting the Demand for Personalized, Accessible Care Traditional weight loss programs often operate on rigid schedules that are difficult for working adults, caregivers, or individuals with disabilities to accommodate

These are the studies worth knowing about

Liquids bypass this issue

I've nothing really to add to what I've put on the main forum

Pfizer halted development of its oral GLP-1 danuglipron in 2025 after a trial participant developed liver injury, reflecting safety concerns that require ongoing monitoring with real-world data